María José Buzón Gómez I am a researcher with extensive training in virology and immunology and a strong interest in translational research. I am dedicated to the study of new therapies aimed at curing HIV, with special emphasis on the characterization, both in blood and in different tissues, of new cellular reservoirs of HIV and the development of strategies that enhance the immune system. Recently part of my research has been directed to the study of SARS-CoV-2. Institutions of which they are part Head of group Infectious Diseases Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Email María José Buzón Gómez LinkedIn Twitter Orcid Email Institutions of which they are part Head of group Infectious Diseases Vall Hebron Institut de Recerca I am a researcher with extensive training in virology and immunology and a strong interest in translational research. I am dedicated to the study of new therapies aimed at curing HIV, with special emphasis on the characterization, both in blood and in different tissues, of new cellular reservoirs of HIV and the development of strategies that enhance the immune system. Recently part of my research has been directed to the study of SARS-CoV-2.
Since 2015, I am the head of the HIV Translational Research Laboratory, located at the Vall d'Hebron Research Institute (VHIR), which belongs to the Infectious Diseases Department. I obtained my PhD in 2010 at AIDS Research Institute, Irsicaixa in Barcelona, and completed my postdoctoral training at the Ragon Institute of MGH, MIT and Harvard in Boston, where I was promoted to Instructor in Medicine at Harvard Medical School in 2014. My scientific interest has focused on the study of the HIV reservoirs that persist despite antiretroviral therapy (ART). I provided the first evidence that new rounds of cryptic viral replication were happening in the presence of ART (Nat Med 2010), and identified reservoir cells with stem-cell-like properties contributing to HIV long-term persistence (Nat Med 2014). My investigations are now focused on the characterization of new cellular reservoirs, the identification of novel latency reversal agents, and the design of new immune-targeted approximations aimed at depleting the latent reservoir. Recently, my lab has identified the new marker CD20 as a potential target for the transcriptionally active HIV reservoir (Nat Com 2019), has characterized the fraction of virus that can be awakened with current latency reversal agents in different populations (Plos Path 2019), and has developed new nanotechnological strategies for the elimination of the viral reservoir (NanoToday 2021). Besides, I am also a member of several evaluation panels (MINECO and AES grant calls), act as an abstract reviewer for several congresses (CROI, IAS and GESIDA), and participate in different scientific committees and international collaborative networks (BEAT-HIV Delaney Collaboratory Group). I have also contributed to innovation with 3 research patents. Importantly, I have been a recipient of several awards, including the CFAR Young Investigator Award (Harvard University Center for AIDS Research), the MGH ECOR Tosteson Award and the “International Raising Talents 2016” from the L'Oreal-Unesco Foundation For Women in Science. A complete list of publications can be found here https://www.ncbi.nlm.nih.gov/myncbi/1TwfYvrCsLtkW/bibliography/public/
Projects Incorporació Dr. Esteve Ribera a la RETICS en SIDA IP: - Collaborators: Adria Curran Fàbregas, Vicenç Falcó Ferrer, Inmaculada Ocaña Rivera, Estrella Caballero Requero, Ariadna Rando Segura, David Perea Pérez, Pere Soler Palacín, María José Buzón Gómez, Paula Suanzes Diez, Jordi Navarro Mercadé, Joaquin Burgos Cibrian, Nerea Sanchez Gaona, Joan Rey Cano, Meritxell Genesca Ferrer, Marie Antoinette Frick, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas, Adria Curran Fàbregas Funding agency: Instituto de Salud Carlos III Funding: 247500 Reference: RD16/0025/0007 Duration: 01/01/2017 - 30/06/2022 Characterization of in vivo resting CD4 T cells expressing HIV RNA in ART-treated individuals Grant Number: 5R21AI118411-02 IP: María José Buzón Gómez Collaborators: Judit Grau Exposito Funding agency: National Institutes of Health (NIH) Funding: 271011.41 Reference: MICROTAR_NIH2015 Duration: 01/08/2015 - 31/07/2018 Desarrollo de una nueva estrategia terapéutica inmune-específica para la erradicación del VIH IP: María José Buzón Gómez Collaborators: Manuel Crespo Casal, Estrella Caballero Requero Funding agency: Ministerio Economía, Industria y Competitividad Funding: 181500 Reference: SAF2015-67334-R Duration: 01/01/2016 - 31/12/2018 Identificación de reactivadores de latencia viral que actúen en células linfocitarias T CD4+ de larga vida como terapia para curar la infección por el VIH. IP: María José Buzón Gómez Collaborators: - Funding agency: L'Oréal España Funding: 15000 Reference: 2015/LOREAL/BUZON Duration: 01/01/2016 - 31/12/2016 Pagination First page « Previous page ‹ … Page 5 Page 6 Page 7 Current page 8 Page 9 Next page › Last page »
